Loading
Matinas BioPharma Holdings, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by STERN ADAM K, was filed 24 Aug 2020.
Matinas BioPharma Holdings, Inc.: what insiders have been doing
Matinas BioPharma Holdings, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Between 22 October 2025 and 22 October 2026, 1 insider published 3 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Compared with its exchange (2,023 companies, median 41 filings), a count of 3 filings is below the norm. Over the whole record (from 2017), the tally stands at 28 purchases and no sales.
No insider has bought Matinas BioPharma Holdings, Inc. shares on the open market in the past twelve months. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 34 days. For comparison, the SEC allows two business days to file a Form 4.
Other companies in the same sector with recent insider buying flagged by our signals: Xenon Pharmaceuticals Inc. and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
121
Thresholds
n/a
Buy Volume
€1M
28 ops. · all time
Sell Volume
n/a
n/a
Since the insiders bought
- +3.3%Entry US$40.55 · Close at T+365 US$41.90
- -11.6%Entry US$44.55 · Close at T+365 US$39.40
- +74.7%Entry US$32.35 · Close at T+365 US$56.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.70
Analyst consensus
Income statement
EBITDA-US$6.5M
Net income-US$11M0.0% margin
Valuation
P/Book0.4x
Beta2.08
Balance sheet & cash
Market capUS$1.7M
Total debtUS$1.4M
Free Cash Flow-US$7M
Debt / Equity0%
Profitability & ownership
ROE-141.2%
ROA-56.2%
% insiders23.8%
% institutions2.2%
Last declaration on 13 August 2026
Declarations121 total
630,335 shares@ US$0.357.52% mcap55.2% of flowCommon Stock, par value $0.0001 per shareSEC:0000921895-26-002109:2
92,100 shares@ US$0.644614.7% of flowCommon Stock, par value $0.0001 per shareSEC:0000921895-26-002109:0
344,710 shares@ US$0.3576.53% mcap30.2% of flowCommon Stock, par value $0.0001 per shareSEC:0000921895-26-002109:1
494,622 shares0Common Stock, par value $0.0001 per shareSEC:0001493152-22-018581:1
1,358,122 shares0Common Stock, par value $0.0001 per shareSEC:0001493152-22-018581:2
1,358,122 shares0Common Stock, par value $0.0001 per shareSEC:0001493152-22-018581:3
494,622 shares0Common Stock, par value $0.0001 per shareSEC:0001493152-22-018581:0
7,859 shares0Common StockSEC:0000905718-22-000007:0
6,106 shares0Common StockSEC:0001493152-21-024397:0
462,150 shares0Common Stock, par value $0.0001 per shareSEC:0001493152-21-022716:0
1,280,917 shares0Common Stock, par value $0.0001 per shareSEC:0001493152-21-016565:1
1,280,917 shares0Common Stock, par value $0.0001 per shareSEC:0001493152-21-016565:0
10,244 shares0Common StockSEC:0001493152-21-015878:0
20,000 shares0Common Stock, par value $0.0001 per shareSEC:0000905718-21-000822:1
200,000 shares0Common Stock, par value $0.0001 per shareSEC:0000905718-21-000824:1
24,000 shares0Common Stock, par value $0.0001 per shareSEC:0000905718-21-000828:1
12,000 shares0Common Stock, par value $0.0001 per shareSEC:0000905718-21-000826:1
24,000 shares0Common Stock, par value $0.0001 per shareSEC:0000905718-21-000832:1
30,000 shares0Common Stock, par value $0.0001 per shareSEC:0000905718-21-000830:1
8,000 shares0Common Stock, par value $0.0001 per shareSEC:0000905718-21-000822:0
40,000 shares0Common Stock, par value $0.0001 per shareSEC:0000905718-21-000824:0
4,800 shares0Common Stock, par value $0.0001 per shareSEC:0000905718-21-000832:0
4,800 shares0Common Stock, par value $0.0001 per shareSEC:0000905718-21-000828:0
2,400 shares0Common Stock, par value $0.0001 per shareSEC:0000905718-21-000826:0
6,000 shares0Common Stock, par value $0.0001 per shareSEC:0000905718-21-000830:0
25 of 121 declarations
About Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc. (MTNB) is a U.S.-listed biopharmaceutical company traded on NYSE American, headquartered in Bedminster, New Jersey, United States. Founded in May 2013, the company was built around a clear thesis: improve the delivery of hard-to-formulate anti-infective therapies through its proprietary lipid nanocrystal (LNC) platform, also described in its materials as a cochleate/encochleated delivery approach. For French-speaking investors, this is a classic clinical-stage biotechnology story: high R&D intensity, limited current commercial visibility, and a valuation that depends heavily on clinical, regulatory, and financing milestones. ([matinasbiopharma.com](https://www.matinasbiopharma.com/investors/sec-filings/annual-reports/content/0001493152-23-007726/0001493152-23-007726.pdf?utm_source=openai))
The company’s pipeline is currently centered on two lead programs. MAT2203 is Matinas’ flagship asset: an oral formulation of amphotericin B, a potent antifungal agent that is traditionally administered intravenously. The company is developing MAT2203 to potentially provide a safer, more convenient oral option for serious fungal infections, including invasive aspergillosis. MAT2501 is the second core program: an oral formulation of amikacin aimed at difficult bacterial infections, including nontuberculous mycobacteria (NTM) and other resistant pathogens. Matinas also positions its LNC platform as a broader enabling technology that could support future programs in inflammation and oncology. ([matinasbiopharma.com](https://www.matinasbiopharma.com/lnc-technology/mat2203?utm_source=openai))
Read moreShow less
From a competitive perspective, Matinas is not a commercial-stage pharmaceutical company with approved products and recurring sales. Instead, it seeks to differentiate itself through drug-delivery innovation in anti-infectives, with the goal of converting IV-only medicines into oral therapies that may reduce toxicity and improve patient convenience. That proposition is scientifically attractive, but execution remains the key risk: the company still depends on clinical data, regulatory interactions, and potential strategic partnerships to advance its pipeline. ([matinasbiopharma.com](https://www.matinasbiopharma.com/investors/news-events/press-releases/detail/248/matinas-biopharmas-lead-antibacterial-development?utm_source=openai))
Recent developments matter materially for the equity story. In April 2026, Matinas disclosed that it had received a notice of non-compliance from NYSE American regarding continued listing standards, tied to stockholders’ equity and a history of losses. During 2025, the company focused mainly on board refreshment and governance changes, while continuing to highlight MAT2203 as its lead program. For investors, this creates a profile with meaningful scientific upside, but also elevated balance-sheet and listing-risk considerations. ([matinasbiopharma.com](https://www.matinasbiopharma.com/investors/sec-filings/all-sec-filings/content/0001493152-26-015170/form8-k.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
